🔗 Share this article

Given that America undertakes historic changes to its vaccine schedules, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccinations during the pandemic and has concentrated on potential deaths following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Schedule

Agency leaders planned to unveil major changes to the pediatric vaccination calendar in December, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would put the US at odds with many the world with no evidence for benefit. The announcement has been postponed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this calendar year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the drug and vaccine divisions as Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has repeatedly called for halting some pediatric shot schedules in the US in order to be more similar to Denmark, a nation with nationalized medicine and a number of inhabitants approximately the population of Wisconsin’s.

In her initial comments, she has continued to focus on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s CBER – rather than drug regulation.

Questions Over Qualifications

The appointee has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, stated Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a large organization. She is not an expert in industry regulation.”

Previous commissioners of the center would “grasp laws and regulations and the science of medication creation”, said a former acting FDA commissioner. “Objectively, she lacks the type of experience that previous people who led the center have had.”

The drug center has an enormous workload at the agency, she emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic drug division authorizes thousands of generic drugs. There is also a biosimilars program, non-prescription drug unit and more, and all of those must be supervised,” she explained. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a major leadership aspect to the role, which oversees in excess of 5,000 personnel. “It’s a massive leadership role, if you do it right,” the former official concluded.

Official Statement and Controversial Policies

When asked about concerns about Høeg’s fitness for the role and whether this selection signifies increased cooperation among FDA leaders on vaccines, a spokesperson stated that the “inquiries stem from flawed presumptions”.

“Her resume matches the responsibilities of her position,” the official said, citing the period Høeg spent advising the agency head on “drug safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's new expedited review system, a disputed rapid drug-approval program that apparently troubled her predecessors. “By what process are these medications being selected for this fast-track system? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards less stringent regulations of most medications, aside from immunizations.”

Established Track Record on Vaccines

Regarding immunizations, Høeg has a clearer, if troubling, history, critics said. She released a study using unconfirmed public submissions to assess the rate of myocarditis after COVID-19 vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the new administration included altering rules for novel immunizations and discontinuing “non-essential” vaccines, she said after the election on a podcast. At the FDA, Dr. Høeg has reportedly proposed barring teenage boys from receiving COVID-19 vaccines.

“She’s an complete dogmatist who commences with her conclusions and works backwards to accommodate the science in a very deceptive, untruthful way,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|